Background: Type-1 diabetes (T1D) is characterized as a heterogenous autoimmune disease. Immune system factors are important in the pathogenesis of T1D. Chemokines as crucial members of the immune system are key factors in the pathogenesis of several autoimmune diseases, including T1D. They are potent chemotactic cytokines with various functions varied from maturation, trafficking of leukocytes, to angiogenesis, angiostasis, and homing of stem cells. Therefore, the current study was aimed to examine if the expression of pro-angiogenic CXC chemokines like CXCL1 and anti-angiogenic chemochines such as CXCL9 are associated with duration and complications of T1D in Iranian diabetic patients. Methods: In this experimental study, blood samples were collected from 209 T1D patients and 189 healthy controls. The serum levels of CXCL1 and CXCL9 were measured by ELISA. Demographic data were also collected on a questionnaire which was designed specifically for this study. Results: Increased plasma levels of chemokines studied (CXCL1 and CXCL9) were observed in T1D patients compared to controls. Current findings also demonstrated that there was a close association between chemokines and complications of T1D and chemokines were elevated in T1D patients suffering complications. Conclusions: Our results probably suggest that the serum levels of CXCL1 and CXCL9 play important roles in T1D pathogenesis. It is also worth noting that these factors are useful prognostic and/or diagnostic biological markers in T1D patients. (Clin. Lab. 2013;59:531-537.
INTRODUCTION
T1D prevalence is increasing globally by 3 -5% annually with considerable variation in different geographic regions (1) . Finland with the highest yearly incidence of 64 cases per 100,000 of population diagnosed and Sweden with more than 40 new cases per 100,000 of population yearly top the list (2) . These countries are in contrast to China and Venezuela with less than one case per 100,000 of population (3) . T1D is a serious disease, usually occurring in children at a young age and accompanied by autoimmune facilitated destruction of the insulin expressing pancreatic β-cells which in turn lead to _____________________________________________ Manuscript accepted August 5, 2012 insulin deficiency (4) . Frequent complications of T1D are retinopathy, nephropathy, neuropathy, and atherosclerosis (5) . T1D is also associated with increased microvascular complications and inflammation (6) . Recent studies demonstrated that T1D is a pro-inflammatory state as evidenced by increased circulating levels of CRP (C-reactive protein), sCD40L, and pro-inflammatory chemokines and cytokines (7) (8) (9) (10) . Chemokines play critical roles in the regulation of defensive actions and reconstruction of damaged tissues (11) . Chemokines are small protein molecules weighting 8 -10 kDa which recruit immune cells to the damaged tissues, eliminate infectious agents and repair infected tissues (11) . Chemokines interact with their corresponding seven transmembrane G protein-coupled rhodopsin-like receptors on the cell surfaces (12) . Four main groups of chemokines (CC, CXC, CX3C, and C) have been identified to date. CXCL1 and CXCL9 are pro-inflammatory chemokines and fit in the CXC group (13) . CXCL1 exhibits angiogenesic properties, while CXCL9 is antiangiogensic (14) . The recent characterization of the CX CR3 (the CXCL9 and CXCL10 specific receptor) demonstrated that it is involved in the development of autoimmune diseases, especially by creating local amplification of inflammation in target organs (15) . Similar to CXCL10, CXCL9 is also expressed by a wide variety of cell types following exposure to cytokines including IFN-α/β and IFN-γ. Several studies have reported key roles of these molecules as important components of host responses in viral infections and in autoimmune diseases (16) . CXCL9 as an IFN-γ inducible chemokine is involved in attracting activated Th1 and NK cells expressing the CXCR3 receptor (17) . This chemokine also plays a role in lymphocyte recruitment in the other autoimmune disorders such as thyroid disorders (18) , demyelinating neuropathies (19) and T1D diabetic patients (20) . In contrast to other members of the CXC chemokine subgroup, (e.g., CXCL10 and CX CL12) with a few reports available regarding their expression in T1D, little is known about the other chemokines such as CXCL1 and CXCL9. Therefore, this project was aimed to examine the serum levels of CXCL1 and CXCL9 in Iranian T1D patients based on duration of the disease, the disease severity, and clinical complications.
MATERIALS AND METHODS
Peripheral blood samples were collected from 209 T1D diabetic patients and 189 healthy controls in Mashhad and Rafsanjan (Eastern part of Iran). Patients and controls were selected from the Rafsanjan population with similar demographic characteristics including gender, age, and duration of diabetes (Table1). The occurrence of T1D was diagnosed by expert internists and pediatricians according to the clinical and paraclinical findings such as drug therapy, fasting blood sugar (FBS) (mg/dL) and the levels of hemoglobin A1C (HbA1C) (%). The nephropathic and retinopathic complications were diagnosed according to the KDOQI criteria and indirect ophthalmoscopy, respectively (21) ( Table 1) . Hb A1c was measured using a commercial kit (Biosystems S.A., Spain) according to the manufacture's guidelines. The principle of the kit was based on the cationic exchange resin. The serum levels of glucose were also assessed using a glucose colorimetric assay kit (Man Ltd, Tehran, Iran). In order to inhibit glycolysis, the serum was separated from whole blood immediately after laboratory arrival. The ethical approval of this study was granted by the local ethical committee of the Rafsanjan University of Medical Sciences and all patients and controls signed informed consent forms prior to sample collection.
Assessment of chemokine serum levels
The serum levels of CXCL1 and CXCL9 were measured by enzyme linked immunosorbent assay (ELISA) (R&D systems, UK) in patients and healthy controls. Assays were performed according to the manufacturer's guidelines. The sensitivity of kits was 2 pg/mL and inter-and intra-assay assessments of reliability of the kit were conducted. Data were only used when the interand intra-assays produced scores of CV < 14% and CV < 3%, re-spectively.
Statistical analysis
Statistical analysis of the differences between groups was determined by Mann Whitney U Test using EPI 2000 and SPSS software version 13. A p-value of less than 0.05 was considered significant.
RESULTS
Results of the current study demonstrated that the mean age of T1D patients was 30 ± 5 years, while, it was 40 ± 12 in control group. The mean ratio of male to female in T1D patients and controls were 51%/49% and 54%/ 46%, respectively ( Table 1 ). The mean duration of being diabetic in T1D patients was 10 ± 4 years. As analysis of our data indicated that 73% of T1D patients were treated with a combination of Neutral Protamine Hagedorn (NPH) and crystal insulin. Only 22% received NPH alone and 5% of T1D patients were treated with a combination of NPH and regular insulin ( Table 4 ). The mean levels of FBS in T1D patients and control subjects were 227.6 ± 8.9 and 93.3 ± 0.79, respectively. We found that the mean HbA1C was 9.1 ± 0.23% and 5.3 ± 0.13% in T1D patients and controls, respectively (Table 1) . A summary is presented in Table  2 . The mean circulating levels of CXCL1 were 400.9 ± 90.5, 612.3 ± 173.9, 1018.2 ± 202.3, 591.8 ± 210.2, 1372.3 ± 43.8, 781.6 ± 327.7, and 132.7 ± 21.28 (pg/ mL) in T1D patients with neuropathy, retinopathy, combined retinopathy and neuropathy, nephropathy, combined retinopathy and foot diabetic syndrome (FDS), combined nephropathy and neuropathy complications, and control subjects, respectively. Analysis of our data also showed that the mean circulating levels of CXCL9 were 383.3 ± 69.4, 564.6 ± 257.9, 1089.1 ± 246.7, 424 ± 160, 1591.1 ± 19.4, 646.5 ± 224, and 112.7 ± 12.9 (pg/mL) in T1D patients with neuropathy, retinopathy, combined retinopathy and neuropathy, nephropathy, combined retinopathy and FDS, combined nephropathy and neuropathy complications, and control subjects, respectively.
Overall, these results showed that the CXC chemokines studied are significantly increased in T1D patients with clinical complications and this enhancement is related to the type of complication, so that the highest circulating level was observed in T1D patients with FDS and the lowest was observed in T1D patients showing only neuropathy (Table 2 ). When compared in T1D patients, there was a positive correlation between the levels of chemokines CXCL1 and CXCL9 with age and duration of being diabetic (Table 3) .
DISCUSSION
The present study was undertaken to explore the role for CXC chemokines in the pathogenesis of T1D. Both patients and controls were chosen from the same ethnic background and all of participants shared a similar geographic living area in the Eastern part of Iran. The significance of chemokines and their related receptors, which play a fundamental part in the initiation and development of T1D, was investigated over the last decade (22) . In our study we demonstrated that circulating CX CL1 and CXCL9 were increased in T1D patients in comparison to controls. Interestingly, our unpublished data also revealed that the serum levels of CXCL10 and CXCL12 were also increased in T1D patients. The increased levels of chemokines in T1D patients in this study probably could be a result of T1D related complications. It has been shown that the attachment of monocytes to ICAM-I is facilitated by some of these chemokines which are inducible by TNF-α and IL-1β inflammatory mediators (23) . Furthermore, these CXC chemokines are inducible and it has been demonstrated that these chemokines are induced by pro inflammatory cytokines (24) , thus, these mediators may accelerate the development of an inflammatory response in T1D patients. Again, our results may explain a mechanism by which the induced levels of these CXC chemokines in T1D patients may confirm a story that is indirectly regulated by some other inflammatory chemokines (25) . TNF-α and IL-1 were increased in T1D patients and our previous investigations showed that TNF-α and IFN-γ induced expression of CXCL1 in some cell types, including primary hepatocytes and hepatoma cells. In our more recent articles we also reported elevated CX CL1 levels in type-2 diabetes (26). However, our previous data also showed elevated serum levels of CXCL10 in type-2 diabetes patients (26) . It might be interesting to note that elevated levels of CXC chemokines may not be related to autoimmunity of T1D patients and probably is related to the high levels of glucose in TID and also probably is related to the T1D complications rather than autoimmunity. Thus, it is possible that recruitment of CXCR1 and CX CR3 expressing cell types, in response to their corresponding ligands (CXCL1 and CXCL9), may lead to development of T1D. As we showed, there was a positive correlation between circulatory levels of all of the investigated CXC chemokines and diabetes complications (Table 2) . T1D, mostly following a pattern of proinflammatory state and elevation of these chemokines, probably is as a result of an inflammatory response which occurs during T1D. CXCL1 and CXCL9 are categorized as pro-inflammatory chemokines and their over expression is reported elsewhere (24) . Thus, the elevated levels of these CXC chemokines in T1D patients may be related to diabetes complications rather than T1D itself, hence, the elevated CXC chemokines in T1D could be implicated as a useful biological tool for the prediction of the diabetes-associated complications. Therefore, T1D complications could be expected with elevated levels of these chemokine serum levels and this may aid preventing organ failure due to T1D complications.
Our results, in a way, demonstrated that the serum levels of chemokines could be used as key biomarkers in T1D prognosis. It may also be concluded that elevated CX-C chemokine levels assist in the progression of T1D and a relationship could be assumed between these chemokines and autoimmunity in the patients (27) .
In the regulatory region of CXCL1 and CXCL9, the regulatory motifs for the various signaling transduction pathways such as heat shock element, NF-KB, and IFN-γ regulatory motifs are present (22, 24) . Thus, the over expression of these chemokines could be due to the activation of these regulatory motifs and may also be related to external stimuli in T1D patient's circulation such as TNF-α and IFN-γ as proinflammatory mediators. Finally, financial limitations and limitations in access to some of molecular biology materials in our country (Iran) did not allow us to perform mRNA studies to analyse the mRNA levels of these chemokines. It is of paramount importance to address the mRNA changes of these chemokines using Real Time PCR analysis in T1D patients in parallel with protein levels, and we hope to do so in our future studies. Additionally, further investigations need to be performed for the examination of the expression of corresponding receptors for these chemokines (e.g., CXCR3, CXCR4 and CXCR7) on either peripheral leukocytes or organ recruited leukocytes (in case of diabetes complications). This help to speculate about the possible role for the chemokine/receptor axis in T1D.
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